Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.


Seyfarth Shaw LLP announced today that Jamaica P. Szeliga has joined the firm’s Litigation department as a partner in Seyfarth’s Washington, D.C. office. Szeliga comes from Leydig, Voit & Mayer, LTD, an intellectual property boutique, where she served as a member in Washington, D.C.
Szeliga’s practice focuses on intellectual property litigation relating to biotechnology and pharmaceutical matters, where she has handled Abbreviated New Drug Application (ANDA) litigation on behalf of a variety of companies. In addition, she has litigated cases involving biologics, medical devices, telecommunications, electronics, consumer goods, and mechanical products.

“Jamaica is a seasoned trial lawyer and adviser to companies facing both basic patent and Hatch-Waxman litigation,” said Kate Perrelli, chair of Seyfarth’s Litigation department. “This is a significant step in our growth strategy for the Intellectual Property practice and in the life sciences space nationally.”

Szeliga has deep experience in patent litigation and has participated in numerous bench and jury trials. She has regularly coordinated complex fact discovery, managed expert discovery, drafted dispositive motions, taken and defended fact and expert depositions, examined witnesses at trial, and briefed multiple appeals. Her versatile practice also includes patent prosecution and opinion drafting, including biosimilar targets. Szeliga has also provided guidance on the licensing and protection of intellectual property in corporate transactions.

“Jamaica’s addition strengthens our local Intellectual Property presence and she will be a key asset to our national team,” said Robert Bodansky, managing partner of Seyfarth’s Washington, D.C. office. “She is an impressive litigator and our IP group, and office as whole, are excited to collaborate with her as we continue to grow.”
Szeliga received her J.D., magna cum laude, from Harvard Law School. She earned a B.S. in Chemistry, with distinction, from Stanford University.

Thomas Haag, co-chair of Seyfarth’s Life Sciences and Chemical Patent team stated, “We are delighted to be bringing Jamaica on board as we continue to build on the firm’s expertise in contentious IP matters related to pharmaceuticals and biosimilars.”

Szeliga’s arrival follows the recent arrivals of Dean Fanelli, Ph.D. and Thomas Haag, Ph.D., co-founders of top intellectual property boutique Fanelli Haag PLLC in Washington, D.C. The office also recently added real estate partner Thomas Galli, corporate partner John Shire, and healthcare partner William Eck. Founded in 1971, Seyfarth’s Washington, D.C. office has grown to over 70 lawyers, with practices spanning ADA Title III, commercial litigation, construction law and litigation, corporate, employee benefits, immigration, intellectual property litigation, government contracts, labor and employment, patent prosecution, and real estate.